ABOUT US

Omniox is an IND stage biotechnology company founded based on H-NOX technology developed in Michael Marletta’s laboratory at the University of California, Berkeley. We are developing the breakthrough H-NOX platform technology into first-in-class and best-in-class OMX oxygen delivery vehicles that treat a range of significant unmet medical needs where tissue hypoxia drives disease pathology and worsens patient outcomes. Our in-house team is composed of the company Co-Founders and experienced scientific and biotechnology professionals, and our advisory boards include world-leading experts in the appropriate fields of medicine, science, and business. Omniox has received grants and other funding from the National Cancer Institute, National Institute of Neurological Disorders and Stroke, the Wellcome Trust, and private investors.

Vision

To pioneer innovative oxygen-based therapies that restore health to patients.

Mission

To solve difficult clinical problems where hypoxia plays a central role. Through rigorous science and world-class partnerships, we are developing our proprietary oxygen-delivery platform to provide meaningful therapeutic benefit to patients.

Values

Scientific and operational excellence
  • Passionate, versatile, and exceptional scientific teams
  • Transparent, effective and diligent business practices
Respect
  • Respected for the integrity and quality of our science
  • Respectful of employees, patients, investors and collaborators
Open-mindedness and courage
  • Curious about hard problems and creative in developing solutions
  • Fearless in the face of challenges and committed to successful outcomes

MANAGEMENT

Stephen Cary

Stephen Cary, PhD

Co-Founder & CEO

Stephen Cary is the co-founder and CEO of Omniox, and co-inventor of the H-NOX technology. Stephen identified H-NOX as a potential therapeutic platform while working at the University of California, Berkeley. He secured the first financial support for Omniox by winning the inaugural Rogers Family Foundation "Bridging the Gap" Award at QB3. Subsequently, Stephen and his team obtained multiple NIH SBIR awards and a Wellcome Trust Translation Award to build Omniox' operations and enable development of the H-NOX platform.

Prior to launching Omniox, Stephen worked at Genentech in Market Strategy, and before that in Immunology Research. He participated extensively in early stage development projects, concentrating on strategic processes of transitioning therapeutic candidates from late-stage research to early development, and provided market and endpoint inputs into design of clinical trials. Stephen obtained his PhD in Biological Chemistry with Michael Marletta at the University of Michigan, and his Bachelor of Science degree in Molecular Biophysics & Biochemistry at Yale University.

Ana Krtolica

Ana Krtolica, PhD

VP Research

Ana Krtolica joined Omniox in 2012 and became VP of Research in August 2013. She is responsible for overseeing all preclinical research and collaborations, directing IND efforts for clinical development of H-NOX therapeutics, and managing initiation of clinical studies at the University of California, San Francisco for our Phase 1 clinical trial in glioblastoma.

Prior to joining Omniox, Ana co-founded StemLifeLine, Inc., an early-stage drug discovery company, serving as their CEO and CSO for 6 years. Before moving to industry, Ana worked as a career scientist at Lawrence Berkeley National Laboratory with a joint appointment at the University of California, San Francisco. Ana completed her post-doctoral training with Judith Campisi at the Lawrence Berkeley National Laboratory and obtained her PhD in Biochemistry at the University of Rochester Cancer Center. Ana's research focused on progenitor, stem, and cancer cell biology and the influence of the hypoxic and aging microenvironment on the cell phenotype. Ana has been Principal Investigator on a number of research grants, is a Co-PI on Omniox’ Wellcome Trust Translational Award, authored multiple patent applications, and published more than 30 research papers in peer-reviewed journals, as well as a number of reviews and book chapters.

John Wesley, CFA

VP Finance & Business Development

John Wesley joined Omniox in 2016 to lead business development and finance and has served on the board of directors since 2012. Prior to Omniox, John invested in public and private opportunities at Pequot Capital, H.I.G. Capital, and Concourse Capital. Prior to his investing career, John worked in strategic and financial advisory roles at Bain & Co. and Morgan Stanley. John received an MBA from the Wharton School and a B.S. in economics from Yale University. John is a CFA charterholder.

Jonathan Winger, PhD

Co-Founder and VP, Biochemistry and Manufacturing

Jonathan Winger is co-inventor of the H-NOX technology, company Co-Founder, and Senior Director of Biochemistry and Manufacturing. He directs the design and biochemical characterization of protein variants with the kinetic and stability properties appropriate for each of the diseases in which H-NOX will be used, as well as oversees in-house protein production and quality control. He also manages the transfer of upstream and downstream processes for scale-up and GMP manufacturing of material for toxicology studies and clinical trials.

Jonathan has 18 years of experience in diverse biochemical and biophysical methods for production and study of H-NOX and other heme proteins. He has published a number of peer reviewed research papers, co-authored several book chapters, and is an inventor on multiple patents. Prior to Omniox, he was an American Heart Association Postdoctoral Fellow with John Kuriyan at the University of California, Berkeley, where he developed expertise in biophysical techniques including X-ray crystallography, small-angle X-ray scattering, and NMR. He obtained his PhD in Medicinal Chemistry with Michael Marletta at the University of Michigan, where he used spectroscopy and enzymology to investigate the role of soluble guanylate cyclase (sGC), an H-NOX domain-containing protein, in nitric oxide signaling pathways. Insights gained from this work contributed to the conception and founding of Omniox.

SCIENTIFIC TEAM

Natacha Le Moan

Natacha Le Moan, PhD

Director, Translational Research

Natacha Le Moan joined Omniox in 2012 and since 2015 has been Director of Translational Research. At Omniox, Natacha focuses on bridging pre-clinical model systems and clinical settings by leading multiple translational projects on ischemic disorders and neuro-oncology. Prior to joining Omniox, Natacha did her postdoctoral research at the University of California, San Francisco to study the role of hypoxia/ischemia in the nervous system using animal models of neurodegeneration. She is a neurobiologist with expertise in multiple aspects of ischemic and hypoxic signaling and has extensive experience in both the in vitro and in vivo approaches used to evaluate the efficacy of anti-hypoxia therapeutics in numerous animal models of neurological disorders. Natacha received her PhD from the University of Paris XI in France and has authored numerous peer reviewed scientific publications in prominent journals and is an inventor on multiple patents.

Kevin Leong

Kevin Leong, PhD

Director, Oncology Research

Kevin Leong joined Omniox in 2015 as Director of Oncology Research. He is a cancer biologist with expertise in colorectal and prostate cancers and possesses extensive research experience in the fields of cancer stem cells, drug resistance, angiogenesis, and metastasis. He received his PhD from the Department of Experimental Medicine at the University of British Columbia in Canada. Following the completion of his postdoctoral training in the Department of Molecular Biology at Genentech in California, he transitioned to a Scientist role within Genentech first in the Department of Tumor Biology and Angiogenesis, and subsequently in the Department of Discovery Oncology. His laboratory at Genentech primarily focused on colorectal cancer, with an emphasis on the development of clinically-relevant in vivo tumor models for the investigation of cancer cells responsible for drug resistance and disease relapse. Kevin has authored numerous peer reviewed scientific publications in prominent journals including Nature and Nature Communications and is an inventor on multiple patents.

BOARD OF DIRECTORS

Jeff Samberg, MBA

Chairman of the Board

Jeff Samberg is the Managing Director of Acadia Woods Partners, LLC, a New York based investment partnership that focuses primarily on early stage technology companies. Jeff lived in the San Francisco Bay Area for 15 years where he held a number of high-tech management roles, including Vice President of Corporate Strategy for PeopleSoft Inc., Vice President of Business Development for Wily Technology, and Entrepreneur in Residence for Greylock Partners. Jeff received his MBA from Stanford University's Graduate School of Business and his B.A. with high honors in Economics from Princeton University.

Stephen Cary

Stephen Cary, PhD

Co-Founder & CEO

Stephen Cary is the CEO of Omniox, co-inventor of the H-NOX technology, and company Co-Founder. He is ultimately responsible for executing business and intellectual property strategies, and overseeing project strategy, collaboration management, and overall scientific progress. He ensures Omniox’ scientific development is effectively communicated to potential investors and corporate partners to move the company towards a significant financing event. Under Dr. Cary’s leadership, Omniox has achieved both scientific and financial success, receiving significant funding from the Wellcome Trust, National Cancer Institute, National Institute of Neurological Disorders and Stroke, and private investments.

Prior to launching Omniox, Stephen worked in market strategy and commercial development at Genentech, where he was awarded three Genentech Excellence Awards. He participated extensively in early stage development projects, concentrating on strategic processes of transitioning therapeutic candidates from late-stage research to early development, and provided market and endpoint inputs into design of Phase I and Phase II clinical trials. Stephen received his first financial support to commercialize H-NOX proteins as therapeutics during his PhD via the Rogers Family Foundation “Bridging the Gap” Award. Stephen obtained his PhD in Biological Chemistry with Michael Marletta at the University of Michigan.

John Wesley, CFA

Director

John Wesley joined Omniox in 2016 to lead business development and finance and has served on the board of directors since 2012. Prior to Omniox, John invested in public and private opportunities at Pequot Capital, H.I.G. Capital, and Concourse Capital. Prior to his investing career, John worked in strategic and financial advisory roles at Bain & Co. and Morgan Stanley. John received an MBA from the Wharton School and a B.S. in economics from Yale University. John is a CFA charterholder.

Dennis Fenton, PhD

Director

Dennis Fenton was granted a PhD in Microbiology from Rutgers University. He joined Pfizer Central research, working in New Product Development from 1977 – 1981. He joined Amgen at its inception in 1982 as a Research Scientist. During his 26-year Amgen career, he held positions of increasing responsibility, including Vice President of Research, Senior Vice President of Sales and Marketing, and Senior Vice President of Operations. He was Amgen’s first Executive Vice President. He holds five US patents and has published over 50 papers and abstracts. He retired from Amgen in 2008 and is currently an independent consultant and a member of the board of directors of Portola and Pfenex and previously served on the boards of Kythera, Hospira, Dendreon, Xenoport and Genzyme. He is also a member of the board of the Keck Graduate Institute.

SCIENTIFIC AND CLINICAL ADVISORS

Michael Marletta, PhD

Chairman, Scientific Advisory Board

Michael Marletta is a co-inventor of the H-NOX technology and company Co-Founder. As Chair of the Scientific Advisory Board, he works to advise Omniox’ protein development and quality control initiatives. Michael has made fundamental discoveries concerning the biological action of nitric oxide, leading to a molecular understanding of general gas sensing mechanisms in biology. A member of the National Academy of Sciences and the Institute of Medicine, Michael is widely published and serves on the editorial boards of several scientific journals. He is currently Professor of Chemistry and Molecular and Cell Biology and CH and Annie Li Chair in the Molecular Biology of Diseases at the University of California, Berkeley. Previously, he was President, CEO, and Cecil H. and Ida M. Green Professor of Chemistry at the Scripps Research Institute. Prior to that, he was Aldo DeBenedictis Distinguished Professor of Chemistry and Chair of Chemistry at the University of California, Berkeley. Michael has served on numerous Scientific Advisory Boards, including those of N30 Pharmaceuticals, Lycera Corporation, Nitromed, and Viamet Pharmaceuticals, and is a member of the Scientific Management Review Board (SMRB) of the NIH. He received his AB degree in Biology and Chemistry from SUNY Fredonia and his PhD in Pharmaceutical Chemistry at the University of California, San Francisco.

Mario Sznol, MD

Chairman, Clinical Advisory Board

Mario Sznol graduated from Rice University and Baylor College of Medicine (BCM) in Houston, Texas. He trained in internal medicine at BCM and completed a medical oncology fellowship in the Department of Neoplastic Diseases, Mount Sinai Hospital, New York. He spent the next twelve years in the Biologics Evaluation Section (BES), Investigational Drug Branch (IDB), Cancer Therapy Evaluation Program of the National Cancer Institute, and was Head of the BES from 1994-1999. He attended on the inpatient units of the Biological Response Modifiers Program, NCI, from 1988-1996 and the Immunotherapy Service of the Surgery Branch, NCI, from 1997-1999. From 1999-2004 he served as Vice President of Clinical Development and Executive Officer of Vion Pharmaceuticals in New Haven, Connecticut. In 2004 he joined the medical oncology faculty of the Yale University School of Medicine as co-leader of the Melanoma Program and is currently Professor of Internal Medicine, Associate Chief of Medical Oncology, Translational Research Leader of the Melanoma-Renal Cancer Disease-Associated Research Team, and Co-Director of Yale SPORE in Skin Cancer. He has a long-standing interest in and focuses on phase 1 clinical trials of immunotherapy agents and new drug development for melanoma and renal cell carcinoma.